1,811 results on '"Cytidine Diphosphate Choline"'
Search Results
2. Citicholine-Amantadine Trial in Traumatic Brain Injury
- Author
-
Dina Salah Eldin Mahmoud Badre, Assistant Professor
- Published
- 2024
3. Citicoline & Antioxidants in Glaucoma
- Author
-
Luca D'Andrea, Prinicipal investigator
- Published
- 2024
4. Citicoline in Youth Alcohol Use Disorder
- Author
-
Lindsay Squeglia, Associate Professor
- Published
- 2024
5. Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
- Author
-
OPIS Spain
- Published
- 2024
6. Citicoline in Ischemic Stroke, a Randomized Trial
- Author
-
Mohamed G. zeinhom, MD, Dr.
- Published
- 2024
7. Improving Sleep and AD Biomarkers
- Author
-
National Institute on Aging (NIA) and Victoria Pak, Assistant Professor
- Published
- 2024
8. Improving Sleep and Cognition in Alzheimer's Disease
- Author
-
National Institute on Aging (NIA), Goizueta Alzheimer's Disease Research Center (ADRC), and Victoria Pak, Principal Investigator
- Published
- 2024
9. Dysregulation of choline metabolism and therapeutic potential of citicoline in Huntington's disease.
- Author
-
Chang, Kuo‐Hsuan, Cheng, Mei‐Ling, Tang, Hsiang‐Yu, Lin, Chung‐Yin, and Chen, Chiung‐Mei
- Subjects
- *
HUNTINGTON disease , *CYTIDINE diphosphate choline , *ENZYME metabolism , *CHOLINE , *OXIDATIVE stress - Abstract
Huntington's disease (HD) is associated with dysregulated choline metabolism, but the underlying mechanisms remain unclear. This study investigated the expression of key enzymes in this pathway in R6/2 HD mice and human HD postmortem brain tissues. We further explored the therapeutic potential of modulating choline metabolism for HD. Both R6/2 mice and HD patients exhibited reduced expression of glycerophosphocholine phosphodiesterase 1 (GPCPD1), a key enzyme in choline metabolism, in the striatum and cortex. The striatum of R6/2 mice also showed decreased choline and phosphorylcholine, and increased glycerophosphocholine, suggesting disruption in choline metabolism due to GPCPD1 deficiency. Treatment with citicoline significantly improved motor performance, upregulated anti‐apoptotic Bcl2 expression, and reduced oxidative stress marker malondialdehyde in both brain regions. Metabolomic analysis revealed partial restoration of disrupted metabolic patterns in the striatum and cortex following citicoline treatment. These findings strongly suggest the role of GPCPD1 deficiency in choline metabolism dysregulation in HD. The therapeutic potential of citicoline in R6/2 mice highlights the choline metabolic pathway as a promising target for future HD therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Citicoline modulates inflammatory signaling pathways in the spleen of rats exposed to gamma-radiation.
- Author
-
Abdel-Aziz, Nahed and Saif-Elnasr, Mostafa
- Subjects
- *
IMMUNOREGULATION , *CYTIDINE diphosphate choline , *JAK-STAT pathway , *SPLEEN , *CELLULAR signal transduction , *TOTAL body irradiation - Abstract
The spleen has an essential role in immune responses regulation and is considered the biggest peripheral immune organ. Citicoline is used for various brain disorders management. This study aimed to examine the using possibility of citicoline to treat γ-radiation-induced splenic inflammation in rats. Eighteen male albino rats were classified into: Group 1 (control) animals were kept as control. Group 2 (γ-radiation) animals were total-body γ-irradiated with 6 Gy. Group 3 (γ-radiation + citicoline) rats were γ-irradiated with 6 Gy, then injected intraperitoneally with citicoline (300 mg/kg/d) 5 min after irradiation for one week. Levels of TNF-α, IL-1β, iNOS, NF-κB, JAK2, and STAT3 were determined in spleen tissue, along with histopathological examination. Rats exposure to gamma-radiation led to elevation in splenic TNF-α, IL-1β, NF-κB, iNOS, JAK2, and STAT3 levels significantly. Treatment with citicoline after gamma-radiation exposure improved this elevation, and modulated gamma-radiation-induced histopathological alterations. This data showed that citicoline inhibited γ-radiation-induced splenic inflammation via suppressing NF-κB and JAK2/STAT3 signaling pathways in spleen tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Citicoline: A Cholinergic Precursor with a Pivotal Role in Dementia and Alzheimer's Disease.
- Author
-
Gareri, Pietro, Cotroneo, Antonino Maria, Montella, Roberta, Gaglianone, Matteo, and Putignano, Salvatore
- Subjects
- *
ALZHEIMER'S disease , *CYTIDINE diphosphate choline , *GERIATRIC Depression Scale , *MINI-Mental State Examination , *ACETYLCHOLINESTERASE inhibitors - Abstract
Background: Citicoline is a naturally occurring compound with pleiotropic effects on neuronal function and cognitive processes. Objective: Based on previous studies, which shed light on the positive effects of citicoline 1 g when combined with acetylcholinesterase inhibitors (AChEIs) and/or memantine, we further investigated the benefits of citicoline in combination therapy in Alzheimer's disease and mixed dementia. Methods: We integrated the datasets of CITIMEM and CITIDEMAGE, increasing the overall sample size to enhance statistical power. We analyzed data from these two investigator-initiated studies involving 295 patients. The primary outcome was the assessment over time of the effects of combined treatment versus memantine given alone or AChEI plus memantine on cognitive functions assessed by Mini-Mental State Examination (MMSE). The secondary outcomes were the influence of combined treatment on daily life functions, mood, and behavioral symptoms assessed by activities of daily life (ADL) and instrumental ADL, Geriatric Depression Scale, and Neuropsychiatric Inventory Scale. One-hundred-forty-three patients were treated with memantine and/or AChEI (control group), and 152 patients were treated with memantine and/or AChEI plus citicoline 1 g/day orally (Citicoline group). Results: A significant difference in MMSE score was found in the average between the two groups of treatment at 6 and 12 months. Conclusions: This study confirmed the effectiveness of combined citicoline treatment in patients with mixed dementia and Alzheimer's disease, with a significant effect on the increase of MMSE score over time. The treated group also showed a significant reduction in the Geriatric Depression Scale and a significant increase in the instrumental ADL scale. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. 'Citicoline' and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.
- Author
-
Turck, Dominique, Bohn, Torsten, Castenmiller, Jacqueline, De Henauw, Stefaan, Hirsch‐Ernst, Karen Ildico, Knutsen, Helle Katrine, Maciuk, Alexandre, Mangelsdorf, Inge, McArdle, Harry J., Naska, Androniki, Pentieva, Kristina, Thies, Frank, Tsabouri, Sophia, Vinceti, Marco, Bresson, Jean‐Louis, Fiolet, Thibault, and Siani, Alfonso
- Subjects
- *
CYTIDINE diphosphate choline , *EPISODIC memory , *MEMORY , *ZWITTERIONS , *MEMORY disorders , *DEMENTIA patients - Abstract
Following an application from Egde Pharma Sp. z o.o, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Poland, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to citicoline and memory. The Panel considers that the food, citicoline (cytidine 5‐diphosphocholine, CDP‐Choline) inner salt, is sufficiently characterised. Improvement, maintenance or reduced loss of memory is a beneficial physiological effect for middle‐aged or elderly adults encountering age‐associated subjective memory impairment. The applicant identified three pertinent human intervention studies in healthy individuals that investigated the effect of citicoline on memory. In weighing the evidence, the Panel took into account that only one randomised controlled trial in healthy participants showed a beneficial effect of citicoline on episodic memory when consumed at doses of 500 mg/day for 12 weeks, whereas this effect has not been observed in another study using citicoline at doses of 1 g/day for 3 months or supported by data obtained in patients with dementia using doses of 1 g/day for 12 weeks and 12 months. No convincing evidence of a plausible mechanism by which citicoline or any of its components (in addition to their endogenous synthesis) could exert an effect on memory in humans has been provided. The Panel concludes that a cause‐and‐effect relationship has not been established between the consumption of citicoline (CDP‐Choline) inner salt and improvement, maintenance or reduced loss of memory in middle‐aged or elderly adults encountering age‐associated subjective memory impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Plausible use of citicoline as an adjuvant in central nervous system infections: A case report and review of the literature.
- Author
-
HABIBURRAHMAN, MUHAMMAD, SUTOPO, STEFANUS, and SARKOWI, WIDYA KHAIRUNNISA
- Subjects
- *
CYTIDINE diphosphate choline , *LITERATURE reviews , *CEREBRAL malaria , *NEUROLOGICAL disorders , *PLANT protection ,CENTRAL nervous system infections - Abstract
Citicoline has been widely used for the treatment of neurological conditions of the central nervous system (CNS), and exhibit potential for infection management, providing anti-inflammatory, antiviral, antioxidant and neuroprotective properties. The present study describes the case of a 50-year-old male patient co-infected with suspected tuberculosis and COVID-19 affecting the CNS who was treated with citicoline. The study aimed to raise clinical questions and initiate a comprehensive literature review. It also aimed to explore the plausible benefits of the use of citicoline in restoring consciousness and alleviating neurological symptoms in CNS infections. In the literature review, eight studies, including two quasi-experimental studies, five literature reviews, and one case report were found to be relevant to the case of the patient described herein, and they suggested that citicoline demonstrated partial protection against cerebral malaria, prevented encephalitis sequelae when immediately administered, and inhibited coronavirus replication. Additionally, six studies reported the potential of citicoline in the treatment of neurological conditions, such as ethambutol-induced optic neuropathy, stroke, head trauma and CNS infections caused by cerebral malaria and COVID-19, compared to standard therapy. Citicoline shows promise as an adjuvant therapy for neurological complications associated with CNS infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Citicoline in Non-Arteritic Ischemic Optic Neuropathy
- Published
- 2023
15. Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy
- Author
-
DENSMORE pharmaceuticals
- Published
- 2023
16. Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET) (SCARLET)
- Author
-
Elliott Crouser, Professor of Internal Medicine
- Published
- 2023
17. Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders
- Author
-
University of Miami, University of Texas Rio Grande Valley, and Sherwood Brown, MD, PhD, Professor of Psychiatry
- Published
- 2023
18. Metabolomics revealed that toxic cyanobacteria stress reduced the flavor quality of Bellamya aeruginosa.
- Author
-
Yuqi Huang, Jinjie Zhang, Dalun Xu, Xiaohui Ren, Wen Yang, Kaihong Lu, and Jinyong Zhu
- Subjects
CYTIDINE diphosphate choline ,CYANOBACTERIAL blooms ,GLUTAMIC acid ,ADENOSINES ,METABOLOMICS - Abstract
The environmental impact of increased eutrophication and frequent cyanobacterial blooms on the growth and reproduction of aquatic organisms has become increasingly prominent in recent years. Bellamya aeruginosa is a nutrient-rich aquatic snail consumed by humans, and environmental changes may decrease its meat quality. However, the specific characteristics of muscle metabolism and flavor quality in freshwater snails and their response patterns to bloom-forming cyanobacterial stress have not been reported. Therefore, in this study, alterations in metabolites in the snail muscle after following feeding on toxic Microcystis aeruginosa were investigated using untargeted metabolomics. A total of 1,128 metabolites were identified, and the metabolic pathways of unsaturated fatty acid biosynthesis and purine, glutathione, and glycerophospholipid metabolism in snails fed toxic cyanobacteria differed from those in snails fed Chlorella vulgaris. Quantitative analysis showed increased levels of bitter-free amino acids, such as tyrosine, phenylalanine, and histidine, after consuming toxic cyanobacteria for 42 d, whereas a relative decrease was observed in the levels of umami- and sweet-free amino acids, such as glutamic acid, aspartic acid, serine, threonine, and glicine. The muscles of snails fed toxic cyanobacteria exhibited higher hypoxanthine and hypoxanthine nucleoside and lower adenosine triphosphate, adenine nucleotide, adenine nucleoside diphosphate, and hypoxanthine nucleotide contents than those of snails fed C. vulgaris. Furthermore, increased metabolites, such as stearic acid, palmitic acid, and cytidine diphosphate choline, and decreased metabolites, such as docosapentaenoic acid, docosahexaenoic acid, adrenoic acid, and L-glutamic acid, reflect the harmful effects of toxic cyanobacteria on the nutritional value and flesh quality of B. aeruginosa. This study comprehensively evaluated the effects of cyanobacterial blooms on freshwater gastropods, providing an important theoretical basis for the quality, safety, and sustainable development of snails as food and related processing industries. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Protective Effect of Citicoline on Sodium Arsenite-Induced Nephrotoxicity in Mice.
- Author
-
Khodayar, Mohammad Javad, Shirani, Maryam, Nikravesh, Mehrad, Mohammadi, Elaheh, Khorsandi, Laya Sadat, and Shariati, Saeedeh
- Subjects
CYTIDINE diphosphate choline ,NEPHROTOXICOLOGY ,SODIUM arsenite ,ANIMAL models in research ,ANTIOXIDANTS - Abstract
The article focuses on evaluating citicoline's protective effect against nephrotoxicity induced by sodium arsenite in mice, it emphasizes the potential role in mitigating oxidative stress and inflammation. It reports that citicoline effectively reduces histopathological damage and restores the balance in oxidative and antioxidant systems in sodium arsenite-exposed mice, and it highlights the therapeutic promise for kidney protection in arsenic toxicity.
- Published
- 2024
- Full Text
- View/download PDF
20. Optic Nerve Neuroprotection in Glaucoma: A Narrative Review.
- Author
-
D'Angelo, Angela, Vitiello, Livio, Lixi, Filippo, Abbinante, Giulia, Coppola, Alessia, Gagliardi, Vincenzo, Pellegrino, Alfonso, and Giannaccare, Giuseppe
- Subjects
- *
OPTIC nerve , *GLAUCOMA , *MOLECULAR pathology , *NEURODEGENERATION , *CYTIDINE diphosphate choline - Abstract
In recent years, researchers have been interested in neuroprotective therapies as a cutting-edge therapeutic strategy to treat neurodegenerative disorders by shielding the brain system from harmful events. Millions of individuals worldwide suffer from glaucoma, an ocular neurodegenerative disease characterized by gradual excavation of the optic nerve head, retinal axonal damage, and consequent visual loss. The pathology's molecular cause is still mostly unknown, and the current treatments are not able to alter the disease's natural progression. Thus, the modern approach to treating glaucoma consists of prescribing medications with neuroprotective properties, in line with the treatment strategy suggested for other neurodegenerative diseases. For this reason, several naturally derived compounds, including nicotinamide and citicoline, have been studied throughout time to try to improve glaucoma management by exploiting their neuroprotective properties. The purpose of this review is to examine the naturally derived compounds that are currently utilized in clinical practice for neuroprotection in glaucomatous patients based on scientific data, emphasizing these compounds' pivotal mechanism of action as well as their proven therapeutic and neuroprotective benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Synergistic antidepressant-like effect of citicoline and CB 1 agonist in male mice.
- Author
-
Amanzade, Aysan, Khakpai, Fatemeh, and Zarrindast, Mohammad-Reza
- Subjects
- *
CYTIDINE diphosphate choline , *CANNABINOID receptors , *MICE , *IMMOBILIZATION stress , *MICROINJECTIONS , *MIRTAZAPINE - Abstract
Background: The endocannabinoid system plays a key role in the control of many emotional-correlated reactions such as stress, depressed mood, and anxiety. Moreover, citicoline has neuroprotective properties and indicates beneficial effects in the treatment of depressive problems. Acute restraint stress (ARS) is an experimental model used for the induction of rodent models of depression. Objective: This research was designed to assess the effects of intracerebroventricular (i.c.v.) injection of cannabinoid CB1 receptor agents on citicoline-induced response to depression-like behaviors in the non-acute restraint stress (NARS) and ARS mice. Methods: For i.c.v. microinjection, a guide cannula was implanted in the left lateral ventricle of male mice. The ARS model was carried out by movement restraint for 4 h. Depression-related behaviors were assessed by forced swimming test (FST), tail suspension test (TST), and splash test. Results: The results exhibited that the ARS mice showed depressive-like responses. I.c.v. infusion of ACPA (1 μg/mouse) induced an antidepressant-like effect in the NARS and ARS mice by reduction of immobility time in the FST and TST as well as enhancement of grooming activity time in the splash test. On the other hand, i.c.v. microinjection of AM251 dose-dependently (0.5 and 1 μg/mouse) induced a depressant-like effect in the NARS mice. I.p. injection of citicoline (80 mg/kg) induced an antidepressant-like response in the NARS and ARS mice. Furthermore, ACPA (0.25 μg/mouse, i.c.v.) potentiated the antidepressant-like response induced by citicoline (20 mg/kg, i.p.) in the NARS and ARS mice. However, AM251 (0.25 μg/mouse, i.c.v.) reversed the antidepressant-like effect produced by the citicoline (80 mg/kg, i.p.) in the NARS and ARS mice. Interestingly, our results indicated a synergistic effect between citicoline and ACPA based on the induction of an antidepressant-like effect in the NARS and ARS mice. Conclusions: These results suggested an interaction between citicoline and cannabinoid CB1 receptors on the modulation of depression-like behaviors in the NARS and ARS mice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Multimodal Morpho-functional Study in Glaucoma Patients-Citicoline Oral Solution
- Author
-
Dr. Vincenzo Parisi, Head of Neurophysiology and Neurophthalmology Research Unit
- Published
- 2023
23. Evaluation of differential effects of CDP-choline and choline on parasympathetic activity and changes in choline levels with heart rate variability.
- Author
-
KAZDAGLI, Hasan, ALPAY, Suheda, OZEL, Hasan Fehmi, and BARIS, Elif
- Subjects
- *
PARASYMPATHOMIMETIC agents , *DIFFERENTIAL diagnosis , *AUTONOMIC nervous system , *TREATMENT effectiveness , *TREATMENT duration , *HEART beat , *CHOLINE , *NUCLEOTIDES , *ELECTROCARDIOGRAPHY , *PARASYMPATHETIC nervous system , *ANIMAL experimentation , *COMPARATIVE studies , *SALT , *TIME , *EVALUATION - Abstract
Objective: Heart rate variability (HRV) is used to evaluate the autonomic activity of heartbeat. This study aimed to investigate the effects of cholinomimetic drugs cytidine diphosphate-choline (CDP-choline) and choline, on short-term HRV parameters. Materials and Methods: Animals were randomized into three groups; control (0.9% NaCl), choline (100 mg/kg), CDP-choline (400 mg/kg). Electrocardiography recordings were obtained for 45-minutes after treatments with 15-minutes intervals. HRV analyses and total choline level measurements in serum and heart tissues were performed. Results: High frequency power and total power increased in treatment groups, while heart rates were decreased. Low frequency was decreased with choline while very low frequency power decreased with CDP-choline. Choline affected most of the HRV parameters in the first 15 minutes, while the effect of CDP-choline started within 30 minutes. Total choline levels were higher in both treatment groups than in the control while the levels were also higher in the choline group compared to CDP-choline group. Conclusion: This study showed that CDP-choline and choline treatments produced a rapid response to short-term HRV parameters, while increasing tissue choline levels. Moreover, the differences in effects and onset time between the drugs on HRV might be related to tissue choline concentration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. A circuitous route for in vitro multi-enzyme cascade production of cytidine triphosphate to overcome the thermodynamic bottleneck.
- Author
-
Li, Zonglin, Zhong, Yahui, Qing, Zhoulei, and Li, Zhimin
- Subjects
CYTIDINE deaminase ,DRUG synthesis ,DEAMINASES ,URIDINE ,CYTIDINE diphosphate choline ,GLUTAMINE synthetase ,NUCLEIC acids - Abstract
Cytidine triphosphate (CTP), as a substance involved in the metabolism of phospholipids, proteins and nucleic acids, has precise drug effects and is a direct precursor for the synthesis of drugs such as citicoline. In this study, we established an in vitro six-enzyme cascade system to generate CTP. To avoid thermodynamic bottlenecks, we employed a circuitous and two-stage reaction strategy. Using cytidine as the key substrate, the final product CTP is obtained via the deamination and uridine phosphorylation pathways, relying on the irreversible reaction of cytidine triphosphate synthase to catalyze the amination of uridine triphosphate. Several extremophilic microbial-derived deaminases were screened and characterized, and a suitable cytidine deaminase was selected to match the first-stage reaction conditions. In addition, directed evolution modification of the rate-limiting enzyme CTP synthetase in the pathway yielded a variant that successfully relieved the product feedback inhibition, along with a 1.7-fold increase in activity over the wild type. After optimizing the reaction conditions, we finally carried out the catalytic reaction at an initial cytidine concentration of 20 mM, and the yield of CTP exceeded 82% within 10.0 h. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Cognitive Effects of Citicoline on Attention in Healthy Men and Women
- Author
-
Biofortis Clinical Research, Inc.
- Published
- 2023
26. Liposomal Encapsulation of Citicoline for Ocular Drug Delivery.
- Author
-
Bonechi, Claudia, Mahdizadeh, Fariba Fahmideh, Talarico, Luigi, Pepi, Simone, Tamasi, Gabriella, Leone, Gemma, Consumi, Marco, Donati, Alessandro, and Magnani, Agnese
- Subjects
- *
RETINAL ganglion cells , *CYTIDINE diphosphate choline , *INTRAOCULAR pressure , *OPTIC nerve diseases , *POISONS , *NEURAL conduction , *NUCLEAR magnetic resonance , *LIPOSOMES , *PHOSPHOLIPIDS - Abstract
Glaucoma represents a group of neurodegenerative diseases characterized by optic nerve damage and the slowly progressive death of retinal ganglion cells. Glaucoma is considered the second leading cause of irreversible blindness worldwide. Pharmaceutical treatment of glaucoma is critical because of the properties of the ocular barrier that limit the penetration of drugs, resulting in lower systemic bioavailability. This behavior causes the need of frequent drug administration, which leads to deposition of concentrated solutions on the eye, causing toxic effects and cellular damage to the eye. To overcome these drawbacks, novel drug-delivery systems, such as liposomes, can play an important role in improving the therapeutic efficacy of antiglaucomatous drugs. In this work, liposomes were synthesized to improve various aspects, such as ocular barrier penetration, bioavailability, sustained release of the drug, targeting of the tissue, and reduction in intraocular pressure. Citicoline (CDP-choline; cytidine 5′-diphosphocholine) is an important intermediate in the biosynthesis of cell membrane phospholipids, with neuroprotective and neuroenhancement properties, and it was used in the treatment on retinal function and neural conduction in the visual pathways of glaucoma patients. In this study, citicoline was loaded into the 1,2-dioleoyl-sn-glycerol-3-phosphocholine and cholesterol liposomal carrier to enhance its therapeutic effect. The citicoline encapsulation efficiency, drug release, and size analysis of the different liposome systems were investigated using dynamic light scattering, nuclear magnetic resonance, infrared spectroscopy, and ToF-SIMS experiments. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. The Combination of Citicoline and Nicotinamide Mononucleotide Induces Neurite Outgrowth and Mitigates Vascular Cognitive Impairment via SIRT1/CREB Pathway.
- Author
-
Zhao, Ning, Zhu, Xiaofeng, Xie, Luyang, Guan, Xin, Tang, Leilei, Jiang, Guojun, and Pang, Tao
- Subjects
- *
CYTIDINE diphosphate choline , *NAD (Coenzyme) , *MYELIN basic protein , *COGNITION disorders , *NICOTINAMIDE , *SIRTUINS , *VASCULAR dementia - Abstract
Vascular dementia (VD) is characterized with vascular cognitive impairment (VCI), which currently has few effective therapies in clinic. Neuronal damage and white matter injury are involved in the pathogenesis of VCI. Citicoline has been demonstrated to exhibit neuroprotection and neurorepair to improve cognition in cerebrovascular diseases. Nicotinamide adenine dinucleotide (NAD+)-dependent sirtuin (SIRT) signaling pathway constitutes a strong intrinsic defense system against various stresses including neuroinflammation in VCI. Our hypothesis is that the combined use of citicoline and the precursor of NAD+, nicotinamide mononucleotide (NMN), could enhance action on cognitive function in VCI. We investigated the synergistic effect of these two drugs in the rat model of VCI by bilateral common carotid artery occlusion (BCCAO). Citicoline significantly enhanced neurite outgrowth in Neuro-2a cells, and the combination of citicoline and NMN remarkably induced neurite outgrowth in Neuro-2a cells and primary cortical neuronal cells with an optimal proportion of 4:1. In the rat model of BCCAO, when two drugs in combination of 160 mg/kg citicoline and 40 mg/kg NMN, this combination administrated at 7 days post-BCCAO significantly improved the cognitive impairment in BCCAO rats compared with vehicle group by the analysis of the Morris water maze and the novel object recognition test. This combination also decreased microglial activation and neuroinflammation, and protected white matter integrity indicated by the increased myelin basic protein (MBP) expression through activation of SIRT1/TORC1/CREB signaling pathway. Our results suggest that the combination of citicoline and NMN has a synergistic effect for the treatment of VD associated with VCI. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma
- Published
- 2022
29. CDP-choline Treatment in ATS Users
- Author
-
Sujung Yoon, Professor
- Published
- 2022
30. Citicoline in Ischemic Stroke
- Author
-
Kafrelsheikh University and Hossam Shokri, prof
- Published
- 2022
31. Efficacy of citicoline as a supplement in glaucoma patients: A systematic review.
- Author
-
Prinz, Julia, Prokosch, Verena, Liu, Hanhan, Walter, Peter, Fuest, Matthias, and Migliorini, Filippo
- Subjects
- *
VISUAL fields , *CYTIDINE diphosphate choline , *RETINAL ganglion cells , *GLAUCOMA , *INTRAOCULAR pressure - Abstract
Purpose: Glaucoma is a leading cause of irreversible blindness worldwide. Retinal ganglion cells (RGC), the neurons that connect the eyes to the brain, specifically die in glaucoma, leading to blindness. Elevated intraocular pressure (IOP) is the only modifiable risk factor, however, many patients progress despite excellent IOP control. Thus, alternative treatment strategies to prevent glaucoma progression are an unmet need. Citicoline has demonstrated neuroprotective properties in central neurodegenerative diseases. However, conclusive evidence of the effect of citicoline on glaucoma progression is missing. This systematic review investigates first-time the therapeutic potential of citicoline in glaucoma patients. Methods: The present study was conducted according to the PRISMA 2020 statement. PubMed, Web of Science, Google Scholar, and Embase were accessed in July 2023 to identify all clinical studies investigating the efficacy of citicoline on IOP, the mean deviation of the 24–2 visual field testing (MD 24–2), retinal nerve fibre layer (RNFL), and the pattern electroretinogram (PERG) P50-N95 amplitude in glaucoma patients. The risk of bias was assessed using the Review Manager 5.3 software (The Nordic Cochrane Collaboration, Copenhagen) and the Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool. Results: Ten studies were eligible for this systematic review, including 424 patients. The mean length of the follow-up was 12.1 ± 11.6 months. The overall risk of bias was low to moderate. The mean age of the patients was 56.7 years. There were no significant differences in the IOP, MD 24–2, RNFL, or PERG P50-N95 amplitude between patients receiving citicoline and the control group. There was no improvement from baseline to the last follow-up in IOP, MD 24–2, RNFL, or PERG P50-N95 amplitude. Conclusion: There is a lack of sufficient evidence to support that citicoline slows the progression of glaucoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Persistent Cognitive Dysfunction in a Non-Hospitalized COVID-19 Long-Hauler Patient Responding to Cognitive Rehabilitation and Citicoline Treatment.
- Author
-
Monastero, Roberto and Baschi, Roberta
- Subjects
- *
SARS-CoV-2 , *CYTIDINE diphosphate choline , *COVID-19 , *MITOCHONDRIAL pathology , *COGNITIVE rehabilitation , *CORONAVIRUS diseases , *COGNITION disorders - Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is characterized by severe flu-like symptoms, which can progress to life-threatening systemic inflammation and multiorgan dysfunction. The nervous system is involved in over one-third of patients, and the most common neurological manifestations concern the central nervous system, such as headache, fatigue, and brain fog. The activation of innate, humoral, and cellular immune responses, resulting in a cytokine storm and endothelial and mitochondrial dysfunctions, are the main pathophysiological mechanisms of SARS-CoV-2 infection. Citicoline is an exogenous source of choline and cytidine involved in intracellular phospholipid synthesis, which improves blood flow, brain activity, and mitochondrial dysfunction. This report will present the case of a non-hospitalized, 59-year-old female. After a mild form of SARS-CoV-2 infection, the patient developed cognitive disturbances such as forgetfulness and anomia. The multidimensional neuropsychological assessment revealed an impairment in episodic memory with borderline performance in executive and visuospatial functioning. Cognitive rehabilitation and treatment with citicoline 1000 mg/daily led to a marked improvement in symptoms after six months. Early identification of the neurological sequelae of the Coronavirus Disease 2019 (COVID-19) and timely rehabilitation interventions are required in non-hospitalized long-hauler patients with COVID-19. Long-term treatment with citicoline should be considered as potentially effective in improving cognitive functioning in subjects with Post COVID-19 Neurological Syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Citicoline for Supporting Memory in Aging Humans.
- Author
-
Świątkiewicz, Maciej and Grieb, Paweł
- Subjects
- *
CYTIDINE diphosphate choline , *MEMORY disorders in old age , *MILD cognitive impairment , *CHOLINE , *NEUROTRANSMITTERS - Abstract
Citicoline is the generic name of CDP-choline, a natural metabolite presents in all living cells. Used in medicine as a drug since the 1980-s, citicoline was recently pronounced a food ingredient. When ingested, citicoline breaks down to cytidine and choline, which become incorporated into their respective normal metabolic pathways. Choline is a precursor of acetylcholine and phospholipids; these is a neurotransmitter pivotal for learning and memory and important constituents of neuronal membranes and myelin sheaths, respectively. Cytidine in humans is readily converted to uridine, which exerts a positive effect on synaptic function and supports the formation of synaptic membranes. Choline deficiency has been found to be correlated with memory dysfunction. Magnetic resonance spectroscopy studies showed that citicoline intake improves brain uptake of choline in older persons, suggestive of that it shall help in reversing early age-related cognitive changes. In randomized, placebo-controlled trials of cognitively normal middle-aged and elderly persons, positive effects of citicoline on memory efficacy were found. Similar effects of citicoline on memory indices were also found in patients suffering from mild cognitive impairment and some other neurological diseases. Altogether, the aforementioned data provide complex and unambiguous evidence supporting the claim that oral citicoline intake positively influences memory function in humans who encounter age-related memory impairment also in the absence of any detectable neurological or psychiatric disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Citicoline on the Barthel Index: Severe and moderate brain injury.
- Author
-
Mahmoodkhani, Mehdi, Aminmansour, Bahram, Shafiei, Mehdi, Hasas, Mohammadreza, and Tehrani, Donya Sheibani
- Subjects
- *
CYTIDINE diphosphate choline , *BARTHEL Index , *BRAIN injuries , *GLASGOW Coma Scale , *QUADRICEPS muscle - Abstract
INTRODUCTION: Traumatic brain injury (TBI) is a paramount factor in mortality and morbidity. The clinical trials conducted to investigate the efficacy of neuroprotective agents, such as citicoline, as a therapeutic alternative for TBI have presented divergent findings. Therefore, this study aimed to evaluate and compare citicoline's effect on the Barthel Index in patients with severe and moderate brain injury. MATERIALS AND METHODS: The study is a randomized clinical trial. Patients in the case group (35 patients) were treated with citicoline and the control group (34 patients) received a placebo. Data were analyzed using SPSS 16 software. RESULTS: The results showed that changes in the Glasgow Coma Scale, changes in quadriceps muscle force score, Barthel Index score changes, achieving the status without intubation, and spontaneous breathing in patients treated with citicoline were not a statistically significant difference in the two groups (P > 0.05). CONCLUSION: Findings revealed that citicoline did not impact the recovery process of severe and moderate TBI patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Citicoline May Prevent Cognitive Decline in Patients with Cerebrovascular Disease.
- Author
-
Almeria, Marta, Alvarez, Ignacio, Molina-Seguin, Jessica, Besora, Sarah, Buongiorno, Mariateresa, Romero, Silvia, Casas, Laura, Cano, Cristina, Castejon, Judith, Arribas, Sonia, and Krupinski, Jerzy
- Subjects
CYTIDINE diphosphate choline ,CEREBROVASCULAR disease ,COGNITION disorders ,MILD cognitive impairment ,COGNITIVE flexibility ,CENTRAL nervous system - Abstract
Introduction: Neuroprotective drugs such as citicoline could improve cognitive performance and quality of life. We studied the effect of citicoline treatment and its association with Vascular Risk Factors (VRF) and APOE on cognition in patients with Subjective Cognitive Complaints (SCC) and Mild Cognitive Impairment (MCI).Methods: This is an observational and prospective study with citicoline during 12 months follow-up. Eighty-one subjects who met criteria for SCC/MCI, aged 50– 75 years with VRF were included and prescribed citicoline 1g/day. Subjects with previous cognitive impairment and any other central nervous system affection were excluded. Wilcoxon Signed Ranks test and paired samples t-test were used to analyze the change in neuropsychological performance.Results: Mean age of the sample was 68.2 (SD 6.8) years and 26 (32.09%) were females. Fifteen subjects (24.6%) were APOE-ε4 carriers, fifty-six (76.7%) had hypertension, fifty-eight (79.5%) had dyslipidemia, twenty-one (28.8%) had diabetes mellitus and twenty-six (35.6%) had cardiopathy. Thirty-two (43.8%) subjects were diagnosed as SCC and forty-one (56.16%) as MCI. During the follow-up, Tweny-six patients (81.25%) in the group of SCC remained stable, six subjects (18.8%) converted to MCI. Twelve patients (29.9%) with MCI reverted to SCC and twenty-nine patients (70.7%) remained stable. At follow-up, SCC subjects had an improvement in the global language domain (p=0.03), naming (p< 0.001), attention (p=0.01) and visuospatial abilities (p< 0.01). MCI group showed an improvement in the screening test (p=0.03), delayed memory (p< 0.01), global cognition (p=0.04) and in cognitive flexibility (p=0.03). Presence of APOE-ε4 had no impact on the above findings.Discussion: SCC subjects showed an improvement in language and attention domains, while those with MCI performed better after 12 months in total scores of MoCA and RBANS domains, some converting back to SCC. This supports the idea that citicoline may prevent cognitive decline in patients with cognitive deficits. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Effect of Citicoline/Homotaurine on PERG in Primary Open Angle Glaucoma
- Author
-
Rossi, Gemma Caterina Maria, Principal Investigator
- Published
- 2021
37. Valuable effects of lactobacillus and citicoline on steatohepatitis: role of Nrf2/HO-1 and gut microbiota.
- Author
-
El-Baz, Ahmed M., El-Ganiny, Amira M., Hellal, Doaa, Anwer, Hala M., El-Aziz, Hend A. Abd, Tharwat, Ibrahim E., El-Adawy, Mohamed A., Helal, Shehab El-Din M., Mohamed, Menna Tallah A., Azb, Tassnim M., Elshafaey, Hanya M., Shalata, AbdulRahman A., Elmeligi, Sahar M., Abdelbary, Noran H., El-kott, Attalla F., Al-Saeed, Fatimah A., Salem, Eman T., El-Sokkary, Mohamed M. Adel, Shata, Ahmed, and Shabaan, Ahmed A.
- Subjects
- *
CYTIDINE diphosphate choline , *GUT microbiome , *NON-alcoholic fatty liver disease , *LACTOBACILLUS , *FATTY liver - Abstract
Non-alcoholic steatohepatitis (NASH) is a more dangerous form of chronic non-alcoholic fatty liver disease (NAFLD). In the current investigation, the influence of citicoline on high-fat diet (HFD)-induced NASH was examined, both alone and in combination with Lactobacillus (probiotic). NASH was induced by feeding HFD (10% sugar, 10% lard stearin, 2% cholesterol, and 0.5% cholic acid) to rats for 13 weeks and received single i.p. injection of streptozotocin (STZ, 30 mg/kg) after 4 weeks. Citicoline was given at two dose levels (250 mg and 500 mg, i.p.) at the beginning of the sixth week, and in combination with an oral suspension of Lactobacillus every day for eight weeks until the study's conclusion. HFD/STZ induced steatohepatitis as shown by histopathological changes, elevated serum liver enzymes, serum hyperlipidemia and hepatic fat accumulation. Moreover, HFD convinced oxidative stress by increased lipid peroxidation marker (MDA) and decreased antioxidant enzymes (GSH and TAC). Upregulation of TLR4/NF-kB and the downstream inflammatory cascade (TNF-α, and IL-6) as well as Pentaraxin, fetuin-B and apoptotic markers (caspase-3 and Bax) were observed. NASH rats also had massive increase in Bacteroides spp., Fusobacterium spp., E. coli, Clostridium spp., Providencia spp., Prevotella interrmedia, and P. gingivalis while remarkable drop in Bifidobacteria spp. and Lactobacillus spp. Co-treatment with citicoline alone and with Lactobacillus improve histopathological NASH outcomes and reversed all of these molecular pathological alterations linked to NASH via upregulating the expression of Nrf2/HO-1 and downregulating TLR4/NF-kB signaling pathways. These results suggest that citicoline and lactobacillus may represent new hepatoprotective strategies against NASH progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial.
- Author
-
Rossetti, Luca, Goni, Francisco, Montesano, Giovanni, Stalmans, Ingeborg, Topouzis, Fotis, Romano, Dario, Galantin, Eleonora, Delgado-Gonzales, Noemi, Giammaria, Sara, Coco, Giulia, Vandewalle, Evelien, Lemmens, Sophie, Giannoulis, Dimitrios, Pappas, Theofanis, and Manni, Gianluca
- Subjects
- *
CYTIDINE diphosphate choline , *CROSSOVER trials , *QUALITY of life , *OPEN-angle glaucoma , *GLAUCOMA - Abstract
Purpose: This study aims to evaluate whether the use of citicoline oral solution could improve quality of life in patients with chronic open-angle glaucoma (OAG). Design: Randomized, double-masked, placebo-controlled, cross-over study was used. Patients were randomized to one of the two sequences: either citicoline 500 mg/day oral solution-placebo or placebo-citicoline 500 mg/day oral solution. Switch of treatments was done after 3 months; patients were then followed for other 6 months. Follow-up included 3-month, 6-month, and 9-month visits. Outcomes: The primary outcome was the mean change of "intra-patient" composite score of the Visual Function Questionnaire-25 (VFQ-25). after citicoline oral solution vs placebo at 6-month visit as compared with baseline. Methods: The trial was multicenter, conducted at 5 European Eye Clinics. OAG patients with bilateral visual field damage, a mean deviation (MD) ranging from − 5 to − 13 dB in the better eye, and controlled IOP were included. VFQ-25 and SF-36 questionnaires were administered at baseline and at 3-, 6-, and 9-month visits. A mixed effect model, with a random effect on the intercept, accounted for correlations among serial measurements on each subject. Results: The primary pre-specified outcome of the analysis reached statistical significance (p = 0.0413), showing greater improvement after citicoline oral solution. There was an increase in the composite score in both arms compared to baseline, but it was significant only for the placebo-citicoline arm (p = 0.0096, p = 0.0007, and p = 0.0006 for the three time-points compared to baseline). The effect of citicoline was stronger in patients with vision-related quality of life more affected by glaucoma at baseline. Conclusions: This is the first placebo-controlled clinical study evaluating the effect of a medical treatment aiming at improving vision-related quality of life in glaucomatous patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Choline-Containing Phospholipids in Stroke Treatment: A Systematic Review and Meta-Analysis.
- Author
-
Sagaro, Getu Gamo and Amenta, Francesco
- Subjects
- *
STROKE , *PHOSPHOLIPIDS , *HEMORRHAGIC stroke , *CYTIDINE diphosphate choline , *MINI-Mental State Examination - Abstract
Background: Globally, stroke is the second leading cause of death and disability. In different studies conducted previously, the choline-containing phospholipids citicoline and choline alphoscerate have been proposed as adjuvants in the treatment of acute strokes. A systematic review was conducted to provide updated information on the effects of citicoline and choline alphoscerate in patients with acute and hemorrhagic strokes. Methods: PubMed/Medline, Scopus, and Web of Science were searched to identify relevant materials. Data were pooled, and odds ratios (OR) were reported for binary outcomes. Using mean differences (MD), we evaluated continuous outcomes. Results: A total of 1460 studies were reviewed; 15 studies with 8357 subjects met the eligibility criteria and were included in the analysis. In our study, citicoline treatment did not result in improved neurological function (NIHSS < 1, OR = 1.05; 95% confidence interval (CI): 0.87–1.27) or functional recovery (mRS < 1, OR = 1.36; 95% CI: 0.99–1.87) in patients with acute stroke. Choline alphoscerate improved neurological function and functional recovery in stroke patients based on the Mathew's scale and the Mini-Mental State Examination (MMSE). Conclusion: Citicoline did not improve the neurological or functional outcomes in acute stroke patients. In contrast, choline alphoscerate improved neurological function and functional recovery and reduced dependency in stroke patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. 基于代谢组学探究乳酸菌对苏尼特羊脂肪分布和脂肪酸组成的影响.
- Author
-
要铎, 张月, 刘婷, 郭月英, 孙雪峰, and 靳禅片
- Subjects
MONOUNSATURATED fatty acids ,LAURIC acid ,CYTIDINE diphosphate choline ,OLEIC acid ,CHOLINE ,FATTY acids ,LINOLEIC acid ,PALMITIC acid - Abstract
Copyright of Journal of Chinese Institute of Food Science & Technology is the property of Journal of Chinese Institute of Food Science & Technology Periodical Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
41. Role of Citicoline in an in vitro AMD model
- Author
-
Nashine, Sonali and Kenney, M Cristina
- Subjects
Biochemistry and Cell Biology ,Biomedical and Clinical Sciences ,Biological Sciences ,Ophthalmology and Optometry ,Macular Degeneration ,Neurodegenerative ,Aging ,Eye Disease and Disorders of Vision ,1.1 Normal biological development and functioning ,Underpinning research ,Eye ,Cells ,Cultured ,Cytidine Diphosphate Choline ,Humans ,Models ,Biological ,Oxidative Stress ,Protective Agents ,Retinal Pigment Epithelium ,Citicoline ,age-related macular degeneration ,neuroprotection ,RPE ,mitochondria ,Biochemistry and cell biology ,Clinical sciences - Abstract
Citicoline is the exogenous form of the nootropic, Cytidine 5'-diphosphate-choline that exerts its neuroprotective effects in the brain as well as in the eye. The current study characterized the cytoprotective effects of purified Citicoline in transmitochondrial AMD (Age-related Macular Degeneration) RPE cybrid cells which carry diseased mitochondria from clinically characterized AMD patients. The effects of Citicoline were examined via flow cytometry analysis of AnnexinV/ PI-stained cells, IncuCyte live-cell imaging analysis to quantify cells undergoing caspase-3/7-mediated apoptosis, analyses of gene expression profiles of apoptosis, hypoxia, and angiogenesis markers, and measurement of ROS levels and cell viability. Our results demonstrated that Citicoline when added exogenously alleviates apoptotic effects as evidenced by diminished AnnexinV/PI and Caspase-3/7 staining, downregulation of apoptosis genes, enhanced cell viability, and reduced oxidative stress in AMD RPE cybrid cells. In conclusion, our study identified Citicoline as a protector in AMD RPE cybrid cells in vitro. However, further studies are required to establish the merit of Citicoline as a cytoprotective molecule in AMD and to decipher the molecular underpinnings of its mechanism of action in AMD.
- Published
- 2020
42. Citicoline, Creatine, and Omega-3 Effects in Middle Age Women
- Author
-
Deborah Yurgelun-Todd, Professor of Psychiatry
- Published
- 2021
43. The Impact of Air Travel on Passenger Cognitive Functions
- Author
-
Dinara Zhumanbayeva, head of laboratory
- Published
- 2021
44. Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases
- Author
-
Dr. Vincenzo Parisi, MD
- Published
- 2021
45. The Role of Citicoline and Coenzyme Q10 in Retinal Pathology.
- Author
-
García-López, Claudia, García-López, Verónica, Matamoros, José A., Fernández-Albarral, José A., Salobrar-García, Elena, de Hoz, Rosa, López-Cuenca, Inés, Sánchez-Puebla, Lidia, Ramírez, José M., Ramírez, Ana I., and Salazar, Juan J.
- Subjects
- *
CYTIDINE diphosphate choline , *MACULAR degeneration , *RETINAL diseases , *PATHOLOGY , *UBIQUINONES , *DIABETIC retinopathy - Abstract
Ocular neurodegenerative diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration are common retinal diseases responsible for most of the blindness causes in the working-age and elderly populations in developed countries. Many of the current treatments used in these pathologies fail to stop or slow the progression of the disease. Therefore, other types of treatments with neuroprotective characteristics may be necessary to allow a more satisfactory management of the disease. Citicoline and coenzyme Q10 are molecules that have neuroprotective, antioxidant, and anti-inflammatory properties, and their use could have a beneficial effect in ocular neurodegenerative pathologies. This review provides a compilation, mainly from the last 10 years, of the main studies that have been published on the use of these drugs in these neurodegenerative diseases of the retina, analyzing the usefulness of these drugs in these pathologies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Choline supplements: An update.
- Author
-
Kansakar, Urna, Trimarco, Valentina, Mone, Pasquale, Varzideh, Fahimeh, Lombardi, Angela, and Santulli, Gaetano
- Subjects
CHOLINE ,DIETARY supplements ,CYTIDINE diphosphate choline ,ACETYLCHOLINE ,COGNITIVE ability - Abstract
In this comprehensive review, we examine the main preclinical and clinical investigations assessing the effects of different forms of choline supplementation currently available, including choline alfoscerate (C8H20NO6P), also known as alpha-glycerophosphocholine (a-GPC, or GPC), choline bitartrate, lecithin, and citicoline, which are cholinergic compounds and precursors of acetylcholine. Extensively used as food supplements, they have been shown to represent an effective strategy for boosting memory and enhancing cognitive function. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Role of Citicoline in Patients With Mild Cognitive Impairment.
- Author
-
Bermejo, Pedro E, Dorado, Rodolfo, and Zea-Sevilla, María Ascensión
- Subjects
- *
MILD cognitive impairment , *CYTIDINE diphosphate choline , *DEMENTIA , *VASCULAR diseases , *DIETARY supplements - Abstract
The term mild cognitive impairment (MCI) defines an intermediate state between normal aging and dementia. Vascular cognitive impairment refers to a decline in cognitive function that is caused by or associated with vascular disease and comprises all the spectrum of cognitive impairments, from MCI of vascular origin to vascular dementia. One of the available treatments for cognitive impairment is cytidine diphosphate-choline (CDP-Choline), or citicoline. The objective of the present manuscript is to provide complete evidence about the efficacy of citicoline for MCI, especially of vascular origin, but also due to other neurodegenerative disorders. Citicoline is a pharmaceutical product constituted by the combination of 2 natural molecules (cytidine and choline) and is marketed as a food supplement. It has been proposed to provide neuroprotective effects through diverse mechanisms of action. Taking into account the available literature, citicoline has shown a consistent improvement in cognitive function in patients with MCI, especially of vascular origin. Moreover, it provides beneficial effects on vascular, Alzheimer, and mixed dementias, stroke sequelae, intracerebral hemorrhages, traumatic brain injuries, and neurodegenerative diseases. Long-term treatment with citicoline has also been demonstrated to be well-tolerated and has not been associated with severe adverse events. Citicoline is a safe, well-tolerated, and promising agent with evidenced neuroprotective properties. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Citicoline for the Management of Patients with Traumatic Brain Injury in the Acute Phase: A Systematic Review and Meta-Analysis.
- Author
-
Secades, Julio José, Trimmel, Helmut, Salazar, Byron, and González, José Antonio
- Subjects
- *
CYTIDINE diphosphate choline , *BRAIN injuries , *GLASGOW Coma Scale - Abstract
Background: Citicoline or CDP-choline is a neuroprotective/neurorestorative drug used in several countries for the treatment of traumatic brain injury (TBI). Since the publication of the controversial COBRIT, the use of citicoline has been questioned in this indication, so it was considered necessary to undertake a systematic review and meta-analysis to evaluate whether citicoline is effective in the treatment of patients with TBI. Methods: A systematic search was performed on OVID-Medline, EMBASE, Google Scholar, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Ferrer databases, from inception to January 2021, to identify all published, unconfounded, comparative clinical trials of citicoline in the acute phase of head-injured patients— that is, treatment started during the first 24 h. We selected studies on complicated mild, moderate, and severe head-injured patients according to the score of the Glasgow Coma Scale (GCS). The primary efficacy measure was independence at the end of the scheduled clinical trial follow-up. Results: In total, 11 clinical studies enrolling 2771 patients were identified by the end. Under the random-effects model, treatment with citicoline was associated with a significantly higher rate of independence (RR, 1.18; 95% CI = 1.05–1.33; I2, 42.6%). The dose of citicoline or the administration route had no effect on outcomes. Additionally, no significant effects on mortality were found, and no safety concerns were noticed. Conclusions: This meta-analysis indicates some beneficial effects of citicoline's increasing the number of independent patients with TBI. The most important limitation of our meta-analysis was the presumed heterogeneity of the studies included. Registration: PROSPERO CRD42021238998 [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Choline and citicoline ameliorate oxidative stress in acute kidney injury in rats.
- Author
-
BARIS, Elif, SIMSEK, Oguzhan, ARICI, Mualla Aylin, and TOSUN, Metiner
- Subjects
- *
ACUTE kidney failure , *CYTIDINE diphosphate choline , *CHOLINE , *OXIDATIVE stress , *REACTIVE oxygen species - Abstract
OBJECTIVES: The purpose of this study is to investigate the effects of cholinergic anti-infl ammatory pathway (CAP)-activating drugs, choline and citicoline (Cytidinediphosphate-choline, CDP-choline), on lipopolysaccharide (LPS)-induced acute kidney injury (AKI) parameters and the contribution of NADPH Oxidase4 (NOX4) p22phox. BACKGROUND: Endotoxemia induces a systemic infl ammatory response characterized by the production of pro-infl ammatory mediators and reactive oxygen species (ROS), which eventually develops acute kidney injury (AKI). NADPH Oxidase4 (NOX4) p22phox pathway contributes to the development of endotoxemiainduced AKI. Infl ammatory response can be controlled by CAP. METHODS: Expressions levels of KIM-1, TNF-α, NOX4, p22phox and NFκB in the kidney tissues of rats were analyzed via RT-PCR in experimental groups; 1. Control, 2. LPS (10 mg/kg) + saline, 3. LPS + CDPcholine (375 mg/kg) and 4. LPS + choline (90 mg/kg). Choline and ROS levels in kidney tissues were also measured by a spectrofl uorometric assay. RESULTS: LPS-induced elevations of ROS levels were decreased by CDP-choline or choline administration (p < 0.001). LPS-elevated KIM-1, TNFα, NOX4, p22 phox, and NFκB expressions were signifi cantly decreased by choline or CDP-choline treatments (p < 0.001). CONCLUSION: Decreased ROS production in kidney tissues in treatment groups suggests that choline or CDP-choline may have therapeutic potential in endotoxemia-associated AKI via downregulating NOX4 and p22phox expressions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Divergent Six Month Functional Recovery Trajectories and Predictors after Traumatic Brain Injury: Novel Insights from the Citicoline Brain Injury Treatment Trial Study.
- Author
-
Gardner, Raquel C, Cheng, Jing, Ferguson, Adam R, Boylan, Ross, Boscardin, John, Zafonte, Ross D, Manley, Geoffrey T, and Citicoline Brain Injury Treatment Trial Investigators
- Subjects
Citicoline Brain Injury Treatment Trial Investigators ,Humans ,Cytidine Diphosphate Choline ,Nootropic Agents ,Retrospective Studies ,Cohort Studies ,Longitudinal Studies ,Double-Blind Method ,Recovery of Function ,Randomized Controlled Trials as Topic ,Clinical Trials ,Phase III as Topic ,Brain Injuries ,Traumatic ,Data Science ,TBI ,functional outcome ,predictors ,trajectory ,Rehabilitation ,Physical Injury - Accidents and Adverse Effects ,Neurosciences ,Traumatic Brain Injury (TBI) ,Traumatic Head and Spine Injury ,Brain Disorders ,Injuries and accidents ,Mental health ,Quality Education ,Clinical Sciences ,Neurology & Neurosurgery - Abstract
Cross-sectional approaches to outcome assessment may not adequately capture heterogeneity in recovery after traumatic brain injury (TBI). Using latent class mixed models (LCMM), a data-driven analytic that identifies groups of patients with similar trajectories, we identified distinct 6 month functional recovery trajectories in a large cohort (n = 1046) of adults 18-70 years of age with complicated mild to severe TBI who participated in the Citicoline Brain Injury Treatment Trial (COBRIT). We used multinomial logistic fixed effect models and backward elimination, forward selection, and forward stepwise selection with several stopping rules to explore baseline predictors of functional recovery trajectory. Based on statistical and clinical considerations, the seven-class model was deemed superior. Visualization of these seven functional recovery trajectories revealed that each trajectory class started at one of three recovery levels at 1 month, which, for ease of reference we labeled groups A-C: Group A, good recovery (two classes; A1 and A2); Group B, moderate disability (two classes; B1 and B2); and Group C, severe disability (three classes; C1, C2, and C3). By 6 months, these three groups experienced dramatically divergent trajectories. Group A experienced stable good recovery (A1, n = 115) or dramatic decline (A2, n = 4); Group B experienced rapid complete recovery (B1, n = 71) or gradual recovery (B2, n = 742); Group C experienced dramatic rapid recovery (C1, n = 12), no recovery (C2, n = 91), or death (C3, n = 11). Trajectory class membership was not predicted by citicoline treatment (p = 0.57). The models identified demographic, pre-injury, and injury-related predictors of functional recovery trajectory, including: age, race, education, pre-injury employment, pre-injury diabetes, pre-injury psychiatric disorder, site, Glasgow Coma Scale (GCS) score, post-traumatic amnesia, TBI mechanism, major extracranial injury, hemoglobin, and acute computed tomographic (CT) findings. GCS was the most consistently selected predictor across all models. All models also selected at least one demographic or pre-injury medical predictor. LCMM successfully identified dramatically divergent, clinically meaningful 6 month recovery trajectories with utility to inform clinical trial design.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.